Nirsevimab-alip: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 May 2024

  • curprev 23:4623:46, 13 May 2024‎ Alen Antony talk contribs‎ 5,780 bytes +3,844‎ No edit summary
  • curprev 14:5014:50, 13 May 2024‎ Alen Antony talk contribs‎ 1,936 bytes +1,936‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection..."
Retrieved from "https://www.wikidoc.org/index.php/Nirsevimab-alip"